Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis

References

• Cummings SR, Kelsey JL, Nevitt MC, O’Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7:178–208
   PubMed Web of Science ®Google Scholar
• Holbrook TL, Grazier KL, Kelsey JL, Stauffer RN. The frequency of occurrence, impact and cost of musculoskeletal conditions in the United States. Chicago, IL: American Academy of Orthopedic Surgeons; 1984
   Google Scholar
• EFFO and NOF. Who are candidates for prevention and treatment for osteoporosis? Consensus Development Statement. Osteoporosis Int 1997;7:1–6
   Web of Science ®Google Scholar
• Lindsay R, Burge RT, Strauss DM. One year outcomes and costs following a vertebral fracture. Osteoporosis Int 2005;16:78–85
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Armbrecht G, Felsenberg D, et al. When should the doctor order a spine X-ray? Identifying vertebral fractures for osteoporosis care: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2004;19:1982–93
   PubMed Web of Science ®Google Scholar
• Melton LJ III, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005–10
   PubMed Web of Science ®Google Scholar
• Consensus Development Conference V. Diagnosis, prophylaxis, and treatment of osteoporosis. The A J Med 1993;94:646--50
   Google Scholar
• Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European foundation for osteoporosis and bone disease. The Scientific Advisory Board and the Board of National Societies. Osteoporosis Int 1996;6:256–61
   PubMed Web of Science ®Google Scholar
• Guyatt GH. Evidence-based management of patients with osteoporosis. J Clin Densitom 1998;1:395–402
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Sinclair J, Cook DJ, Glasziou P. Users’ guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. JAMA 1999;281:1836–43
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12
   PubMedGoogle Scholar
• Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, Ltd.; 2006
   Google Scholar
• Chalmers I. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann Ny Acad Sci 1993;703:156–63; discussion 163–165
   PubMed Web of Science ®Google Scholar
• Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609–13
   PubMed Web of Science ®Google Scholar
• Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896–900
   PubMed Web of Science ®Google Scholar
• Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408–12
   PubMed Web of Science ®Google Scholar
• Cochrane GW. The combination of estimates from different experiments. Biometrics 1954;10:101–29
   Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58
   PubMed Web of Science ®Google Scholar
• Black D, Delmas S, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Bone HG, Downs RW, Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab 1997;82:265–74
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. New Engl J Med 1995;333:1437–43
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Parker RA, Ferguson L, et al. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998;13:1431–8
   PubMed Web of Science ®Google Scholar
• Lau EM, Woo J, Chan YH, Griffith J. Alendronate prevents bone loss in Chinese women with osteoporosis. Bone 2000;27:677–80
   PubMed Web of Science ®Google Scholar
• McClung M, Clemmensen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998;128:253–61
   PubMed Web of Science ®Google Scholar
• Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporosis Int 2005;16:468–74
   PubMed Web of Science ®Google Scholar
• Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1–160
   PubMed Web of Science ®Google Scholar
• Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD001155
   Google Scholar
• Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508–16
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, 2009. Alendronate: summary of product characteristics. Available from http://www.emea.europa.eu [last accessed 19 Jun 2012]
   Google Scholar
• Cryer B, Bauer DC. Oral biphosphanates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002;77:1031–43
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Schwartz K, Pinholt EM, et al. Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tissue Int 2010;86:110–5
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. AmJ Med 1995;99:144–52
   PubMed Web of Science ®Google Scholar
• Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488–501
   PubMed Web of Science ®Google Scholar
• Shiraki M, Kushida K, Fukunaga M, et al. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J 1998;45:191–201
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study (Fosamax International Trial Study Group). Osteoporos Int 1999;9:461–8
   PubMed Web of Science ®Google Scholar
• Bell NH, Bilezikian JP, Bone HG III, et al. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 2002;87:2792–7
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. Ann Intern Med 2002;136:742–6
   PubMed Web of Science ®Google Scholar
• Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, et al. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J Bone Miner Metab 2003;21:421–7
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. New Engl J Med 2007;357:1799–809
   PubMed Web of Science ®Google Scholar